Galera Therapeutics (NASDAQ: GRTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.580 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Galera Therapeutics (NASDAQ: GRTX) through any online brokerage.
Other companies in Galera Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Virios Therapeutics (NASDAQ:VIRI), Cabaletta Bio (NASDAQ:CABA), Acurx Pharmaceuticals (NASDAQ:ACXP) and Synaptogenix (NASDAQ:SNPX).
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by B of A Securities on Friday, May 27, 2022. The analyst firm set a price target for 2.00 expecting GRTX to rise to within 12 months (a possible 37.93% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Galera Therapeutics (NASDAQ: GRTX) is $1.45 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Galera Therapeutics.
Galera Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Galera Therapeutics.
Galera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.